BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+0.51%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$9.85B
AUM Growth
+$9.85B
(-3.8%)
Cap. Flow
-$133M
Cap. Flow
% of AUM
-1.35%
Top 10 Holdings %
Top 10 Hldgs %
29.91%
Holding
226
New
13
Increased
56
Reduced
57
Closed
7
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$52.6M |
| 2 |
Revolution Medicines
RVMD
|
$44.1M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$37.4M |
| 4 |
Fate Therapeutics
FATE
|
$37M |
| 5 |
AMED
Amedisys
AMED
|
$36.1M |
Top Sells
| 1 |
Moderna
MRNA
|
$314M |
| 2 |
Halozyme
HALO
|
$53M |
| 3 |
Charles River Laboratories
CRL
|
$47.4M |
| 4 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
$38M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
$30.8M |
Sector Composition
| 1 | Healthcare | 96.84% |
| 2 | Industrials | 0.82% |
| 3 | Technology | 0.59% |
| 4 | Financials | 0.04% |
| 5 | Consumer Discretionary | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Exact Sciences
EXAS
$9.33B
| $41M | 0.42% |
429,273
+153,600
| +56% | +$14.7M |
|
77
ESSA Pharma
EPIX
$11.2M
| $40.3M | 0.41% |
5,034,814
+2,575,000
| +105% | +$20.6M |
|
78
Mersana Therapeutics
MRSN
$34.8M
| $40.2M | 0.41% |
4,261,000
+1,320,000
| +45% | +$12.4M |
|
79
Kezar Life Sciences
KZR
$28.5M
| $39.2M | 0.4% |
4,533,148
| – | – |
|
80
Phreesia
PHR
$1.81B
| $38.4M | 0.39% |
622,542
| – | – |
|
|
81
Halozyme
HALO
$8.75B
| $37.5M | 0.38% |
921,500
-1,302,966
| -59% | -$53M |
|
82
HUTCHMED
HCM
$2.62B
| $36.8M | 0.37% |
1,006,147
+141,387
| +16% | +$5.18M |
|
83
Teleflex
TFX
$5.57B
| $36.8M | 0.37% |
97,818
-2,343
| -2% | -$882K |
|
84
Health Catalyst
HCAT
$228M
| $36.4M | 0.37% |
727,233
-26,388
| -4% | -$1.32M |
|
85
Masimo
MASI
$7.43B
| $34.6M | 0.35% |
127,713
| – | – |
|
|
86
Bio-Rad Laboratories Class A
BIO
$7.8B
| $34.3M | 0.35% |
46,015
-41,286
| -47% | -$30.8M |
|
87
10x Genomics
TXG
$1.66B
| $33.9M | 0.34% |
232,672
| – | – |
|
88
Cooper Companies
COO
$13.3B
| $30.7M | 0.31% |
74,266
| – | – |
|
89
AbbVie
ABBV
$374B
| $30.5M | 0.31% |
282,900
-41,300
| -13% | -$4.45M |
|
90
Quanterix
QTRX
$202M
| $29.6M | 0.3% |
593,819
-43,996
| -7% | -$2.19M |
|
91
Black Diamond Therapeutics
BDTX
$164M
| $29.3M | 0.3% |
3,463,000
| – | – |
|
92
AtriCure
ATRC
$1.73B
| $29.1M | 0.3% |
418,016
+43,598
| +12% | +$3.03M |
|
93
Illumina
ILMN
$15.2B
| $28.4M | 0.29% |
70,130
-5,200
| -7% | -$2.11M |
|
94
Teladoc Health
TDOC
$1.37B
| $27.4M | 0.28% |
215,906
-42,042
| -16% | -$5.33M |
|
95
NeoGenomics
NEO
$1.06B
| $27.1M | 0.28% |
561,683
-256,630
| -31% | -$12.4M |
|
|
96
Charles River Laboratories
CRL
$7.99B
| $26.1M | 0.27% |
63,329
-114,941
| -64% | -$47.4M |
|
|
NVRO
97
DELISTED
NEVRO CORP.
NVRO
| $25M | 0.25% |
214,956
+31,755
| +17% | +$3.7M |
|
98
Axsome Therapeutics
AXSM
$6.09B
| $24.8M | 0.25% |
752,945
+400,924
| +114% | +$13.2M |
|
99
ResMed
RMD
$39.4B
| $23.2M | 0.24% |
88,145
| – | – |
|
100
Outset Medical
OM
$245M
| $22.6M | 0.23% |
457,060
| – | – |
|